Northeast Ohio Medical University, 4209 St Rt 44, PO Box 95, Rootstown, OH, 44272, USA.
The Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Harm Reduct J. 2023 Aug 16;20(1):110. doi: 10.1186/s12954-023-00842-6.
The opioid crisis continues in full force, as physicians and caregivers are desperate for resources to help patients with opioid use and chronic pain disorders find safer and more accessible non-opioid tools.
The purpose of this article is to review the current state of the opioid epidemic; the shifting picture of cannabinoids; and the research, policy, and current events that make opioid risk reduction an urgent public health challenge. The provided table contains an evidence-based clinical framework for the utilization of cannabinoids to treat patients with chronic pain who are dependent on opioids, seeking alternatives to opioids, and tapering opioids.
Based on a comprehensive review of the literature and epidemiological evidence to date, cannabinoids stand to be one of the most interesting, safe, and accessible tools available to attenuate the devastation resulting from the misuse and abuse of opioid narcotics. Considering the urgency of the opioid epidemic and broadening of cannabinoid accessibility amidst absent prescribing guidelines, the authors recommend use of this clinical framework in the contexts of both clinical research continuity and patient care.
阿片类药物危机仍在肆虐,医生和护理人员迫切需要资源,以帮助阿片类药物使用者和慢性疼痛患者找到更安全、更容易获得的非阿片类药物工具。
本文旨在回顾阿片类药物危机的现状;大麻素的变化情况;以及研究、政策和当前事件,这些都使得减少阿片类药物风险成为一个紧迫的公共卫生挑战。本文提供的表格包含了一个基于证据的临床框架,用于治疗依赖阿片类药物、寻求阿片类药物替代品和减少阿片类药物用量的慢性疼痛患者使用大麻素。
基于对现有文献和流行病学证据的全面审查,大麻素有望成为最有趣、最安全、最容易获得的工具之一,可减轻阿片类药物滥用和误用造成的破坏。考虑到阿片类药物危机的紧迫性和大麻素可及性的扩大,而没有处方指南,作者建议在临床研究连续性和患者护理的背景下使用这一临床框架。